Document is current
Any future updates will be listed below
-
Authors
Aschenbrenner, Dominik https://orcid.org/0000-0001-7580-2567
Nassiri, Isar https://orcid.org/0000-0003-1886-1151
Venkateswaran, Suresh
Pandey, Sumeet
Page, Matthew
Drowley, Lauren
Armstrong, Martin
Kugathasan, Subra https://orcid.org/0000-0002-8686-4189
Fairfax, Benjamin https://orcid.org/0000-0001-7413-5002
Uhlig, Holm H. https://orcid.org/0000-0002-6111-7355
-
Funding
Funding for this research was provided by:
UCB | UCB UK (UCB Pharma/Oxford collaboration grant (July 2017 – July 2020))
This research was supported by the NIHR Oxford Biomedical Research Centre. HHU is supported by the Leona M. and Harry B. Helmsley Charitable Trust.
- License Information
-
More Information
Article History
Received: 5 May 2023
Accepted: 25 March 2024
First Online: 28 May 2024
Competing interests
: H.H.U. has received research support or consultancy fees from UCB Pharma, Janssen, Eli Lilly, MiroBio, Celgene and AbbVie. D.A. was supported by a UCB Pharma fellowship. M.P., L.D., and M.A. are employed by and shareholders of UCB Pharma. S.P. is an employee and shareholder of Glaxo Smith Kline. D.A. is an employee and shareholder of Novartis Pharma AG. This article reflects the authors’ personal opinions and not that of their employer. The remaining authors declare no competing interests.
